Fig. 1From: Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort studyKaplan-Meier analysis of (A) progression-free survival and (B) overall survival with nal-IRI plus 5-FU/LVBack to article page